Role of the urologist in whether locoregional prostate cancer patients consult with a radiation oncologist.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16029-e16029
Author(s):  
Ruben G. W. Quek ◽  
Kevin C. Ward ◽  
Viraj A. Master ◽  
Chun Chieh Lin ◽  
Katherine S. Virgo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Clinical Judgment ◽  
Treatment Options ◽  
Critical Role ◽  
Medical Schools ◽  
Initial Therapy ◽  
Radiation Oncologist ◽  
Multilevel Regression ◽  
Institutional Settings

e16029 Background: Multiple treatment options exist for prostate cancer patients, and therapeutic recommendations may differ depending on characteristics of the specialist consulted. The clinical judgment of specialists can play a critical role in the initial treatment choice, especially in cases where there is no professional consensus regarding the optimal treatment strategy. We examined the association between prostate cancer patients’ urologists’ practice affiliation with medical schools on the likelihood the patient would consult a radiation oncologist. Methods: Using the Surveillance, Epidemiology and End Results – Medicare linked database and the American Medical Association Physician Masterfile, we conducted a retrospective cohort study of 39,915 patients aged 66 years or older who were diagnosed between 2004 - 2007 with locoregional prostate cancer, and the 2,404 urologists who performed the diagnostic biopsies. Multilevel regression analysis was used to evaluate the influence of patients’ urologists’ practice affiliations with medical schools on the patients’ consultation with a radiation oncologist within 9 months of diagnosis. Results: Overall, 25,110 (62.9%) patients consulted with a radiation oncologist. After adjusting for patient, tumor and urologist characteristics, patients who saw urologists practicing within non-institutional settings were significantly more likely to consult with a radiation oncologist (odds ratio [OR], 1.19; 95% confidence interval [95% CI], 1.05-1.34, p = 0.006) when compared to those who saw urologists practicing within settings with a major medical school affiliation. In addition, patients who saw urologists ≥ 58 years old were significantly more likely to consult with a radiation oncologist (OR, 1.71; 95% CI, 1.16-2.50, p = 0.006) when compared to those who saw urologists < 43 years old. Conclusions: Locoregional prostate cancer patients who received their diagnostic biopsy by urologists practicing in non-institutional settings and those who saw older urologists were significantly more likely to eventually consult with a radiation oncologist. This may have implications on which patient eventually receives radiation as initial therapy.

Associations between patient knowledge of others' experiences and treatment choice in men with localized prostate cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6578-6578
Author(s):  
Aaron J. Katz ◽  
Ying Cao ◽  
Xinglei Shen ◽  
Deborah Usinger ◽  
Sarah Walden ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
North Carolina ◽  
Cancer Patients ◽  
Treatment Options ◽  
Population Based ◽  
Treatment Choice ◽  
Localized Prostate Cancer ◽  
The North ◽  
Patient Reported

6578 Background: Men with localized prostate cancer must select from multiple treatment options, without one clear best choice. Consequently, personal factors, such as knowing other prostate cancer patients who have undergone treatment, may influence patient decision-making. However, associations between knowledge about others’ experiences and treatment decision-making among localized prostate cancer patients has not been well characterized. We used data from a population-based cohort of localized prostate cancer patients to examine whether patient-reported knowledge of others’ experiences is associated with treatment choice. Methods: The North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) is a population-based cohort of localized prostate cancer patients enrolled from 2011-2013 throughout the state of North Carolina in collaboration with the North Carolina Central Cancer Registry. All patients were enrolled prior to treatment and followed prospectively. Patient decision-making factors including knowledge of others’ experiences with prostate cancer treatment options were collected through patient report. Patient treatment choice was determined through medical record abstraction and cancer registry data. Results: Among 1,202 patients, 17% reported knowing someone who pursued active surveillance (AS) while 28%, 46%, and 59% reported knowing someone who received brachytherapy, external beam radiation (EBRT), or radical prostatectomy (RP), respectively; 26% underwent AS, 9% brachytherapy, 21% EBRT, and 39% RP as their initial treatment. In unadjusted analyses, patients with knowledge of others’ experiences with brachytherapy, EBRT or RP had more than twice the odds of receiving that treatment compared to patients who did not. Knowledge of others’ experience with AS was not associated with choice to undergo AS. Multivariable analysis adjusting for age, race, risk group, and patient-reported goals of care showed knowledge of others’ experiences with brachytherapy (OR 4.60, 95% confidence interval [CI] 2.76 to 7.68), EBRT (OR 2.38, 95% CI 1.69 to 3.34), or RP (OR 4.02, 95% CI 2.84 to 5.70) was significantly associated with odds of receiving that treatment. The odds of receiving a particular treatment option were further increased among patients who reported knowing someone who had a “good” experience with the treatment in question. Conclusions: This is the first population-based study to directly demonstrate the impact of a patient’s knowledge of others’ experiences on treatment choice in prostate cancer. These data provide a new consideration to clinicians in their counseling of patients with newly diagnosed prostate cancer, and also impacts research into the informed decision-making process for this disease.

scholarly journals The Use of Ultrasound Imaging in the External Beam Radiotherapy Workflow of Prostate Cancer Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-16 ◽  
Author(s):  
Saskia M. Camps ◽  
Davide Fontanarosa ◽  
Peter H. N. de With ◽  
Frank Verhaegen ◽  
Ben G. L. Vanneste
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Ultrasound Imaging ◽  
Organs At Risk ◽  
External Beam Radiotherapy ◽  
Treatment Options ◽  
Current Status ◽  
Tumor Control ◽  
External Beam ◽  
Image Guided Radiotherapy

External beam radiotherapy (EBRT) is one of the curative treatment options for prostate cancer patients. The aim of this treatment option is to irradiate tumor tissue, while sparing normal tissue as much as possible. Frequent imaging during the course of the treatment (image guided radiotherapy) allows for determination of the location and shape of the prostate (target) and of the organs at risk. This information is used to increase accuracy in radiation dose delivery resulting in better tumor control and lower toxicity. Ultrasound imaging is harmless for the patient, it is cost-effective, and it allows for real-time volumetric organ tracking. For these reasons, it is an ideal technique for image guidance during EBRT workflows. Review papers have been published in which the use of ultrasound imaging in EBRT workflows for different cancer sites (prostate, breast, etc.) was extensively covered. This new review paper aims at providing the readers with an update on the current status for prostate cancer ultrasound guided EBRT treatments.

scholarly journals Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

2020 ◽  
Vol 10 ◽  
Author(s):  
Samantha S. Sigurdson ◽  
Francisco E. Vera-Badillo ◽  
Fabio Ynoe de Moraes
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Options ◽  
Hormone Sensitive

Urinary dysfunction appears to be the primary determinant of castration versus observation for prostate cancer patients with PSA failure

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14621-14621
Author(s):  
J. A. Zagory ◽  
C. Chang ◽  
S. Knight ◽  
E. A. Lyons ◽  
C. L. Bennett
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Watchful Waiting ◽  
Specific Antigen ◽  
Hormonal Treatment ◽  
Initial Therapy ◽  
Urinary Dysfunction ◽  
Definitive Treatment ◽  
Psa Failure ◽  
Decision Satisfaction

14621 Background: After undergoing definitive treatment for a primary localized disease, prostate cancer patients may experience a rise in their prostate specific antigen (PSA) levels. Treating PSA failure with hormonal treatment has many health related quality of life (HRQOL) implications, including urinary, bowel, sexual, and male hormonal problems. Predictors of choice between hormonal treatment versus watchful waiting have not been investigated. Methods: Patients were approached after consecutive rises in PSA levels (n = 31). Patients completed HRQOL and decision satisfaction questionnaires, and a literacy assessment. Results: Patients were between 56 and 85 years old; 55% were African American. 71% of African Americans and 50% of whites had low functional literacy. 58% of patients chose hormonal therapy to treat their PSA rise; 81% of patients reported urinary problems. All patients reported decision satisfaction (see Table). Factors associated with castration versus watchful waiting were primarily related to poor urologic function, and were not specifically prostate cancer related (dysuria, nocturia, urination frequency). Conclusions: Primary treatment of urinary dysfunction, rather than castration, should be evaluated as initial therapy for prostate cancer patients with PSA failure. [Table: see text] No significant financial relationships to disclose.

Perceptions regarding prostate cancer (CaP) treatment options: Results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6530-6530 ◽  
Author(s):  
Ronald C. Chen ◽  
Matthew Edward Nielsen ◽  
Bryce B. Reeve ◽  
Laura H. Hendrix ◽  
Robert P Agans ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sexual Function ◽  
Treatment Options ◽  
Population Based ◽  
Robotic Prostatectomy ◽  
External Beam Radiation ◽  
Radiation Oncologist ◽  
Beam Radiation ◽  
The North ◽  
Published Evidence

6530 Background: NC ProCESS is a population-based cohort of early (non-metastatic) CaP patients followed prospectively from diagnosis. Methods: Patients were identified through Rapid Case Ascertainment of the NC Cancer Registry from all NC counties in 2010-12. Phone survey assessed perceptions regarding treatment options and priorities in treatment selection. Results: 937 (59% of all eligible) completed this survey. Median age was 65; 72% were Caucasian. At time of survey, ~13 weeks from diagnosis, 98% had discussed options with a urologist, 49% with primary care, and 41% radiation oncologist. Many patients had concerns about potential effects of surgery and radiation on ability to perform daily activities, recovery time, and burden to family (Table). Open prostatectomy (ORP) and external beam radiation (RT) were deemed most likely to affect urinary and sexual function; fewer reported concern with robotic prostatectomy (RALP). Only 32% reported hormonal therapy would affect sexual function. Most reported surgery (especially RALP) had the best chance for cure, while 59% worried about recurrence with RT. In almost all questions, patients who consulted only with a urologist had significantly different perceptions about treatment options than those who also consulted with a radiation oncologist. In choosing treatment, 61% reported that cure was the highest priority, and 28% indicated preserving quality of life. Conclusions: Modern CaP patients often have misconceptions about treatment options inconsistent with published evidence, which are partially mitigated by multidisciplinary consultation. Most indicated cure as the highest priority, and surgery offers the best chance of cure. [Table: see text]

scholarly journals Evaluation of Quality of Life for Prostate Cancer Patients Who Have Undergone Radical Prostatectomy Surgery

2007 ◽  
Vol 1 (4) ◽  
pp. 284-293
Author(s):  
Stephen F. Tomicich
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Sexual Function ◽  
Cancer Patients ◽  
Treatment Option ◽  
Surgical Procedure ◽  
Treatment Options ◽  
Aging Men

Prostate cancer is an epidemic among aging men. It is essential that research be conducted with the purpose of determining the outcomes of various treatment options. For this study, a sample of radical prostatectomy patients completed a written questionnaire for the purpose of evaluating whether the radical prostatectomy for clinically localized prostate cancer has an effect on quality of life. In addition, demographic factors were examined to determine if they had an effect on quality of life after this surgical procedure. Data appeared to show that urinary, bowel, and sexual function are determinants of quality of life that are affected by having the radical prostatectomy procedure. Due to the numerous treatment options available for prostate cancer, more research regarding quality of life should be undertaken to determine the best possible treatment option for the patient.

The Role of the Urologist in Whether Locoregional Prostate Cancer Patients Consult With a Radiation Oncologist

2013 ◽  
Vol 87 (2) ◽  
pp. S485-S486
Author(s):  
R.G.W. Quek ◽  
K.C. Ward ◽  
V.A. Master ◽  
C.C. Lin ◽  
K.S. Virgo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Radiation Oncologist

Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16101-e16101
Author(s):  
L. von Boehmer ◽  
P. Wild ◽  
L. Keller ◽  
T. Hermanns ◽  
M. Provenzano ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune Responses ◽  
Cancer Patients ◽  
Late Stage ◽  
Treatment Options ◽  
Antigen Expression ◽  
Castration Resistant Prostate Cancer ◽  
Specific Antibodies ◽  
Ct Antigens ◽  
Cancer Testis

e16101 Background: Prostate cancer (PC) is the most frequent malignancy in men and it continues to be one of the most common fatal cancers. Treatment options in advanced castration-resistant prostate cancer (CRPC) are limited. Cancer testis (CT) antigens are expressed in a variety of human cancers, but not in normal tissues except for MHC deficient spermatogonia, and represent promising targets for immunotherapy. Little is known about CT antigen expression in relation to disease progression. The aim of this study was to investigate which CT antigens are expressed and immunogenic and hence represent promising targets for patients with prostate cancer and correlate these findings with clinicopathological characteristics. Methods: To determine the expression of 6 CT antigens in prostate cancer immunohistochemistry was performed on tissue micro arrays. We investigated 6 CT antigens (NY-ESO.1, MAGE-C1, MAGE-C2, GAGE, MAGE-A1 and MAGE-A4) in benign hyperplasia (n=45), early (n=388) and late stage (n=71) prostate cancer. To determine the occurrence of spontaneous antibodies against cancer testis antigens, ELISA and Western blot was performed for NY-ESO-1, MAGE-C1 and MAGE-C2 with sera from prostate cancer patients. Results: CT antigens are increasingly expressed in late stage prostate cancers. As an exception we found MAGE-C2 to be expressed early in the course of disease, frequently inducing MAGE-C2 specific antibodies. In later stage metastatic prostate cancer patients NY-ESO-1 is more often expressed, inducing NY-ESO-1 specific antibodies. Conclusions: Cancer testis (CT) antigens are prognostic markers, frequently inducing immune responses and may be suitable for immunotherapeutic intervention in patients with prostate cancer. No significant financial relationships to disclose.

Advanced Prostate Cancer: Considerations for Advanced Practitioners

2021 ◽  
Vol 12 (3) ◽  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Advanced Prostate Cancer ◽  
Treatment Options ◽  
Genetics And Genomics

At JADPRO Live Virtual 2020, Brenda Martone, MSN, ANP-BC, AOCNP®, discussed treatment options available for advanced prostate cancer patients and the role of genetics and genomics in patients with advanced prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document